<DOC>
	<DOCNO>NCT00334828</DOCNO>
	<brief_summary>The purpose study compare eritoran tetrasodium placebo patient severe sepsis demonstrate reduction mortality cause .</brief_summary>
	<brief_title>ACCESS : A Controlled Comparison Eritoran Tetrasodium Placebo Patients With Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<criteria>INCLUSION CRITERIA : Age &gt; = 18 year Confirmed earlyonset severe sepsis , define : oObjective evidence infection likely cause bacterial fungal pathogen oPresence least 3 4 systemic inflammatory response syndrome ( SIRS ) criterion oSepsisassociated organ dysfunction Baseline Acute Physiology Chronic Health Evaluation II ( Apache II ) Score 21 37 &lt; 12 hour onset first qualify organ dysfunction expect administration study drug A commitment full patient support EXCLUSION CRITERIA : Pregnancy breastfeed Extensive ( &gt; 20 % Body Surface Area ) thirddegree burn Weight &gt; 150 kg admission Patients whose death sepsis consider imminent Patients expect survive least 2 month due preexist uncorrectable medical condition , chronic vegetative state Patients severe congestive heart failure Patients currently receive immunosuppressive therapy cyclosporine , azathioprine , cancer chemotherapy Patients granulocyte count &lt; 1000/mm^3 unless decrease count believe due sepsis Patients require cardiopulmonary resuscitation 4 week prior evaluation enrollment Human immunodeficiency virus ( HIV ) positive patient CD4 count &lt; = 50/mm^3 within 4 week enrollment , endstage process Patients significant hepatic impairment , portal hypertension , esophageal varix Patients expect treat endotoxinremoval device Patients active cancer Patients receive polymyxin B colistin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Severe sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>sepsis</keyword>
</DOC>